{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T15:49:23Z","timestamp":1793288963447,"version":"4.5.0"},"reference-count":210,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T00:00:00Z","timestamp":1668816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81901627"],"award-info":[{"award-number":["81901627"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52173145"],"award-info":[{"award-number":["52173145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U20A20360"],"award-info":[{"award-number":["U20A20360"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jilin Provincial Science and Technology Development Program","award":["20210101063JC"],"award-info":[{"award-number":["20210101063JC"]}]},{"DOI":"10.13039\/501100004739","name":"Youth Innovation Promotion Association of the Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["2022226"],"award-info":[{"award-number":["2022226"]}],"id":[{"id":"10.13039\/501100004739","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009991","name":"Department of Finance of Jilin Province","doi-asserted-by":"publisher","award":["JLSCZD2019-036"],"award-info":[{"award-number":["JLSCZD2019-036"]}],"id":[{"id":"10.13039\/501100009991","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The liver is an important organ in the human body and performs many functions, such as digestion, detoxification, metabolism, immune responses, and vitamin and mineral storage. Therefore, disorders of liver functions triggered by various hepatic diseases, including hepatitis B virus infection, nonalcoholic steatohepatitis, hepatic fibrosis, hepatocellular carcinoma, and transplant rejection, significantly threaten human health worldwide. Polymer-based nanomedicines, which can be easily engineered with ideal physicochemical characteristics and functions, have considerable merits, including contributions to improved therapeutic outcomes and reduced adverse effects of drugs, in the treatment of hepatic diseases compared to traditional therapeutic agents. This review describes liver anatomy and function, and liver targeting strategies, hepatic disease treatment applications and intrahepatic fates of polymeric nanomedicines. The challenges and outlooks of hepatic disease treatment with polymeric nanomedicines are also discussed.<\/jats:p>","DOI":"10.1186\/s12951-022-01708-y","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T04:03:59Z","timestamp":1668830639000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Polymeric nanomedicines for the treatment of hepatic diseases"],"prefix":"10.1186","volume":"20","author":[{"given":"Feixiang","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingqian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuguo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunsheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyue","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,19]]},"reference":[{"issue":"1","key":"1708_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jhep.2018.09.014","volume":"70","author":"SK Asrani","year":"2019","unstructured":"Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151\u201371.","journal-title":"J Hepatol"},{"issue":"1","key":"1708_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1708_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3390\/v10050267","volume":"10","author":"L Singh","year":"2018","unstructured":"Singh L, Indermun S, Govender M, Kumar P, du Toit LC, Choonara YE, et al. Drug delivery strategies for antivirals against hepatitis B virus. Viruses. 2018;10(5):267.","journal-title":"Viruses."},{"issue":"3","key":"1708_CR4","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1136\/gut.2008.163527","volume":"58","author":"EK Geissler","year":"2009","unstructured":"Geissler EK, Schlitt HJ. Immunosuppression for liver transplantation. Gut. 2009;58(3):452\u201363.","journal-title":"Gut"},{"key":"1708_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12935-018-0538-7","volume":"18","author":"K Lohitesh","year":"2018","unstructured":"Lohitesh K, Chowdhury R, Mukherjee S. Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018;18:44.","journal-title":"Cancer Cell Int"},{"issue":"12","key":"1708_CR6","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jama.2020.2298","volume":"323","author":"AC Sheka","year":"2020","unstructured":"Sheka AC, Adeyi O, Thompson J, Hameed B, Crawford PA, Ikramuddin S. Nonalcoholic steatohepatitis: a review. JAMA. 2020;323(12):1175\u201383.","journal-title":"JAMA"},{"issue":"2","key":"1708_CR7","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA. Liver fibrosis. J Clin Invest. 2005;115(2):209\u201318.","journal-title":"J Clin Invest"},{"issue":"6","key":"1708_CR8","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.jhep.2011.05.039","volume":"55","author":"LH Reddy","year":"2011","unstructured":"Reddy LH, Couvreur P. Nanotechnology for therapy and imaging of liver diseases. J Hepatol. 2011;55(6):1461\u20136.","journal-title":"J Hepatol"},{"issue":"2","key":"1708_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"MJ Mitchell","year":"2021","unstructured":"Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101\u201324.","journal-title":"Nat Rev Drug Discov"},{"issue":"7870","key":"1708_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/S0140-6736(74)90682-5","volume":"1","author":"G Gregoriadis","year":"1974","unstructured":"Gregoriadis G, Wills EJ, Swain CP, Tavill AS. Drug-carrier potential of liposomes in cancer chemotherapy. Lancet. 1974;1(7870):1313\u20136.","journal-title":"Lancet"},{"issue":"4","key":"1708_CR11","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.nantod.2010.06.007","volume":"5","author":"L Li","year":"2010","unstructured":"Li L, Wang H, Ong ZY, Xu K, Ee PLR, Zheng S, et al. Polymer- and lipid-based nanoparticle therapeutics for the treatment of liver diseases. Nano Today. 2010;5(4):296\u2013312.","journal-title":"Nano Today"},{"key":"1708_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.addr.2020.06.017","volume":"154\u2013155","author":"R Bottger","year":"2020","unstructured":"Bottger R, Pauli G, Chao PH, Al Fayez N, Hohenwarter L, Li SD. Lipid-based nanoparticle technologies for liver targeting. Adv Drug Deliv Rev. 2020;154\u2013155:79\u2013101.","journal-title":"Adv Drug Deliv Rev"},{"issue":"7","key":"1708_CR13","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s11095-006-0284-8","volume":"23","author":"P Couvreur","year":"2006","unstructured":"Couvreur P, Vauthier C. Nanotechnology: intelligent design to treat complex disease. Pharm Res. 2006;23(7):1417\u201350.","journal-title":"Pharm Res"},{"key":"1708_CR14","doi-asserted-by":"publisher","first-page":"109128","DOI":"10.1016\/j.biopha.2019.109128","volume":"117","author":"Z Ma","year":"2019","unstructured":"Ma Z, Zhang B, Fan Y, Wang M, Kebebe D, Li J, et al. Traditional chinese medicine combined with hepatic targeted drug delivery systems: a new strategy for the treatment of liver diseases. Biomed Pharmacother. 2019;117:109128.","journal-title":"Biomed Pharmacother"},{"key":"1708_CR15","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijpharm.2018.12.080","volume":"558","author":"J Siepmann","year":"2019","unstructured":"Siepmann J, Faham A, Clas SD, Boyd BJ, Jannin V, Bernkop-Schn\u00fcrch A, et al. Lipids and polymers in pharmaceutical technology: lifelong companions. Int J Pharm. 2019;558:128\u201342.","journal-title":"Int J Pharm"},{"key":"1708_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/B978-0-12-407722-5.00022-0","volume-title":"Cancer theranostics","author":"X Zhu","year":"2014","unstructured":"Zhu X, Anquillare ELB, Farokhzad OC, Shi J. Chapter 22-polymer- and protein-based nanotechnologies for cancer theranostics. In: Chen X, Wong S, editors. Cancer theranostics. Oxford: Academic Press; 2014. p. 419\u201336."},{"issue":"7","key":"1708_CR17","doi-asserted-by":"publisher","first-page":"2971","DOI":"10.1039\/c2cs15344k","volume":"41","author":"N Kamaly","year":"2012","unstructured":"Kamaly N, Xiao ZY, Valencia PM, Radovic-Moreno AF, Farokhzad OC. Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev. 2012;41(7):2971\u20133010.","journal-title":"Chem Soc Rev"},{"issue":"14","key":"1708_CR18","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.addr.2006.09.011","volume":"58","author":"OC Farokhzad","year":"2006","unstructured":"Farokhzad OC, Langer R. Nanomedicine: developing smarter therapeutic and diagnostic modalities. Adv Drug Deliv Rev. 2006;58(14):1456\u20139.","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"1708_CR19","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2002.20.6.1668","volume":"20","author":"LW Seymour","year":"2002","unstructured":"Seymour LW, Ferry DR, Anderson D, Hesslewood S, Julyan PJ, Poyner R, et al. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol. 2002;20(6):1668\u201376.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1708_CR20","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.nano.2009.01.009","volume":"5","author":"Q Zhou","year":"2009","unstructured":"Zhou Q, Sun X, Zeng L, Liu J, Zhang Z. A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomedicine. 2009;5(4):419\u201323.","journal-title":"Nanomedicine"},{"key":"1708_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12986-019-0331-1","volume":"16","author":"SA Jazayeri-Tehrani","year":"2019","unstructured":"Jazayeri-Tehrani SA, Rezayat SM, Mansouri S, Qorbani M, Alavian SM, Daneshi-Maskooni M, et al. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial. Nutr Metab. 2019;16:8.","journal-title":"Nutr Metab"},{"issue":"4","key":"1708_CR22","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1016\/j.suc.2010.04.017","volume":"90","author":"SRZ Abdel-Misih","year":"2010","unstructured":"Abdel-Misih SRZ, Bloomston M. Liver anatomy. Surg Clin N Am. 2010;90(4):643\u201353.","journal-title":"Surg Clin N Am"},{"issue":"3","key":"1708_CR23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/cmi.2015.97","volume":"13","author":"Z Zhou","year":"2016","unstructured":"Zhou Z, Xu MJ, Gao B. Hepatocytes: a key cell type for innate immunity. Cell Mol Immunol. 2016;13(3):301\u201315.","journal-title":"Cell Mol Immunol"},{"issue":"2 Suppl 1","key":"1708_CR24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hep.21060","volume":"43","author":"V Racanelli","year":"2006","unstructured":"Racanelli V, Rehermann B. The liver as an immunological organ. Hepatology. 2006;43(2 Suppl 1):54\u201362.","journal-title":"Hepatology"},{"issue":"4","key":"1708_CR25","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1002\/cphy.c140078","volume":"5","author":"KK S\u00f8rensen","year":"2015","unstructured":"S\u00f8rensen KK, Simon-Santamaria J, McCuskey RS, Smedsr\u00f8d B. Liver sinusoidal endothelial cells. Compr Physiol. 2015;5(4):1751\u201374.","journal-title":"Compr Physiol"},{"issue":"1","key":"1708_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-5926-1-1","volume":"1","author":"F Braet","year":"2002","unstructured":"Braet F, Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol. 2002;1(1):1.","journal-title":"Comp Hepatol"},{"key":"1708_CR27","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.actbio.2017.05.013","volume":"57","author":"R Tamura","year":"2017","unstructured":"Tamura R, Uemoto S, Tabata Y. Augmented liver targeting of exosomes by surface modification with cationized pullulan. Acta Biomater. 2017;57:274\u201384.","journal-title":"Acta Biomater"},{"issue":"6","key":"1708_CR28","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/sj.mt.6300168","volume":"15","author":"SI Kim","year":"2007","unstructured":"Kim SI, Shin D, Choi TH, Lee JC, Cheon G-J, Kim K-Y, et al. Systemic and specific delivery of small interfering RNAs to the liver mediated by apolipoprotein A-I. Mol Ther. 2007;15(6):1145\u201352.","journal-title":"Mol Ther"},{"key":"1708_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.colsurfb.2018.11.082","volume":"175","author":"T Yang","year":"2019","unstructured":"Yang T, Lan Y, Cao M, Ma X, Cao A, Sun Y, et al. Glycyrrhetinic acid-conjugated polymeric prodrug micelles co-delivered with doxorubicin as combination therapy treatment for liver cancer. Colloids Surf B Biointerfaces. 2019;175:106\u201315.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"6","key":"1708_CR30","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/ar.20663","volume":"291","author":"RS McCuskey","year":"2008","unstructured":"McCuskey RS. The hepatic microvascular system in health and its response to toxicants. Anat Rec (Hoboken). 2008;291(6):661\u201371.","journal-title":"Anat Rec (Hoboken)"},{"issue":"21","key":"1708_CR31","doi-asserted-by":"publisher","first-page":"R1147-51","DOI":"10.1016\/j.cub.2017.09.019","volume":"27","author":"E Trefts","year":"2017","unstructured":"Trefts E, Gannon M, Wasserman DH. The liver. Curr Biol. 2017;27(21):R1147-51.","journal-title":"Curr Biol"},{"key":"1708_CR32","first-page":"1","volume-title":"Practical gastroenterology and hepatology: liver and biliary disease","author":"N Lachman","year":"2010","unstructured":"Lachman N, Pawlina W. The liver and biliary apparatus: basic structural anatomy and variations. In: Nicholas J, Talley MDP, Keith D. Lindor MD, Hugo E. Vargas MD, editors. Practical gastroenterology and hepatology: liver and biliary disease. Oxford: Blackwell Publishing Ltd; 2010. pp.\u00a01\u201316."},{"issue":"7","key":"1708_CR33","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1039\/C1CS15233E","volume":"41","author":"CD Walkey","year":"2012","unstructured":"Walkey CD, Chan WC. Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment. Chem Soc Rev. 2012;41(7):2780\u201399.","journal-title":"Chem Soc Rev"},{"issue":"5","key":"1708_CR34","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.1021\/nn300558p","volume":"6","author":"SH Cheng","year":"2012","unstructured":"Cheng SH, Li FC, Souris JS, Yang CS, Tseng FG, Lee HS, et al. Visualizing dynamics of sub-hepatic distribution of nanoparticles using intravital multiphoton fluorescence microscopy. ACS Nano. 2012;6(5):4122\u201331.","journal-title":"ACS Nano"},{"issue":"1","key":"1708_CR35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0168-3659(99)00015-2","volume":"59","author":"K Ogawara","year":"1999","unstructured":"Ogawara K, Yoshida M, Higaki K, Kimura T, Shiraishi K, Nishikawa M, et al. Hepatic uptake of polystyrene microspheres in rats: effect of particle size on intrahepatic distribution. J Control Release. 1999;59(1):15\u201322.","journal-title":"J Control Release"},{"issue":"1","key":"1708_CR36","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S0014-5793(99)00364-6","volume":"448","author":"EL Romero","year":"1999","unstructured":"Romero EL, Morilla MJ, Regts J, Koning GA, Scherphof GL. On the mechanism of hepatic transendothelial passage of large liposomes. FEBS Lett. 1999;448(1):193\u20136.","journal-title":"FEBS Lett"},{"issue":"1","key":"1708_CR37","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s11095-008-9626-z","volume":"26","author":"JA Champion","year":"2009","unstructured":"Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res. 2009;26(1):244\u20139.","journal-title":"Pharm Res"},{"key":"1708_CR38","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jconrel.2016.01.020","volume":"240","author":"YN Zhang","year":"2016","unstructured":"Zhang YN, Poon W, Tavares AJ, McGilvray ID, Chan WCW. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Release. 2016;240:332\u201348.","journal-title":"J Control Release"},{"issue":"3","key":"1708_CR39","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/S1748-0132(07)70083-X","volume":"2","author":"FX Gu","year":"2007","unstructured":"Gu FX, Karnik R, Wang AZ, Alexis F, Levy-Nissenbaum E, Hong S, et al. Targeted nanoparticles for cancer therapy. Nano Today. 2007;2(3):14\u201321.","journal-title":"Nano Today"},{"issue":"12 Pt 1","key":"1708_CR40","first-page":"6387","volume":"46","author":"Y Matsumura","year":"1986","unstructured":"Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387\u201392.","journal-title":"Cancer Res"},{"issue":"1\u20132","key":"1708_CR41","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","volume":"65","author":"H Maeda","year":"2000","unstructured":"Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1\u20132):271\u201384.","journal-title":"J Control Release"},{"key":"1708_CR42","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","volume":"66","author":"N Bertrand","year":"2014","unstructured":"Bertrand N, Wu J, Xu XY, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2\u201325.","journal-title":"Adv Drug Deliv Rev"},{"issue":"17","key":"1708_CR43","first-page":"3752","volume":"55","author":"F Yuan","year":"1995","unstructured":"Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res. 1995;55(17):3752\u20136.","journal-title":"Cancer Res"},{"issue":"4","key":"1708_CR44","doi-asserted-by":"publisher","first-page":"777","DOI":"10.3390\/molecules23040777","volume":"23","author":"R Farra","year":"2018","unstructured":"Farra R, Musiani F, Perrone F, \u010cema\u017ear M, Kamen\u0161ek U, Tonon F, et al. Polymer-mediated delivery of siRNAs to Hepatocellular Carcinoma: variables affecting specificity and effectiveness. Molecules. 2018;23(4):777.","journal-title":"Molecules"},{"issue":"6","key":"1708_CR45","doi-asserted-by":"publisher","first-page":"e2005236","DOI":"10.1002\/smll.202005236","volume":"17","author":"H Wu","year":"2021","unstructured":"Wu H, Wang MD, Liang L, Xing H, Zhang CW, Shen F, et al. Nanotechnology for hepatocellular carcinoma: from surveillance, diagnosis to management. Small. 2021;17(6):e2005236.","journal-title":"Small"},{"key":"1708_CR46","doi-asserted-by":"publisher","first-page":"102968","DOI":"10.1016\/j.critrevonc.2020.102968","volume":"151","author":"RR Malla","year":"2020","unstructured":"Malla RR, Kumari S, Kgk D, Momin S, Nagaraju GP. Nanotheranostics: their role in hepatocellular carcinoma. Crit Rev Oncol Hematol. 2020;151:102968.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"1708_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejpb.2007.08.001","volume":"69","author":"M Gaumet","year":"2008","unstructured":"Gaumet M, Vargas A, Gurny R, Delie F. Nanoparticles for drug delivery: the need for precision in reporting particle size parameters. Eur J Pharm Biopharm. 2008;69(1):1\u20139.","journal-title":"Eur J Pharm Biopharm"},{"issue":"15","key":"1708_CR48","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1016\/j.addr.2008.08.005","volume":"60","author":"JD Byrne","year":"2008","unstructured":"Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv Drug Deliv Rev. 2008;60(15):1615\u201326.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1708_CR49","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jconrel.2010.08.027","volume":"148","author":"F Danhier","year":"2010","unstructured":"Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release. 2010;148(2):135\u201346.","journal-title":"J Control Release"},{"issue":"1","key":"1708_CR50","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1039\/C9BM01604J","volume":"8","author":"J Li","year":"2020","unstructured":"Li J, Zhang Y, Cai C, Rong X, Shao M, Li J, et al. Collaborative assembly of doxorubicin and galactosyl diblock glycopolymers for targeted drug delivery of hepatocellular carcinoma. Biomater Sci. 2020;8(1):189\u2013200.","journal-title":"Biomater Sci"},{"key":"1708_CR51","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jcis.2019.01.021","volume":"540","author":"J Zhao","year":"2019","unstructured":"Zhao J, Yan C, Chen Z, Liu J, Song H, Wang W, et al. Dual-targeting nanoparticles with core-crosslinked and pH\/redox-bioresponsive properties for enhanced intracellular drug delivery. J Colloid Interface Sci. 2019;540:66\u201377.","journal-title":"J Colloid Interface Sci"},{"issue":"1\u20132","key":"1708_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijpharm.2018.04.028","volume":"545","author":"SP Kuruvilla","year":"2018","unstructured":"Kuruvilla SP, Tiruchinapally G, Kaushal N, ElSayed MEH. Effect of N-acetylgalactosamine ligand valency on targeting dendrimers to hepatic cancer cells. Int J Pharm. 2018;545(1\u20132):27\u201336.","journal-title":"Int J Pharm"},{"issue":"3","key":"1708_CR53","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3109\/1061186X.2013.860982","volume":"22","author":"P Detampel","year":"2014","unstructured":"Detampel P, Witzigmann D, Kr\u00e4henb\u00fchl S, Huwyler J. Hepatocyte targeting using pegylated asialofetuin-conjugated liposomes. J Drug Target. 2014;22(3):232\u201341.","journal-title":"J Drug Target"},{"issue":"20","key":"1708_CR54","doi-asserted-by":"publisher","first-page":"9298","DOI":"10.1039\/C4NR04730C","volume":"7","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Zhang X, Chen T, Wang X, Fu Y, Jin Y, et al. A safe and efficient hepatocyte-selective carrier system based on myristoylated preS1\/21\u201347 domain of hepatitis B virus. Nanoscale. 2015;7(20):9298\u2013310.","journal-title":"Nanoscale"},{"key":"1708_CR55","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2147\/IJN.S240359","volume":"15","author":"A Hefnawy","year":"2020","unstructured":"Hefnawy A, Khalil IH, Arafa K, Emara M, El-Sherbiny IM. Dual-ligand functionalized core-shell chitosan-based nanocarrier for hepatocellular carcinoma-targeted drug delivery. Int J Nanomed. 2020;15:821\u201337.","journal-title":"Int J Nanomed"},{"issue":"2","key":"1708_CR56","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.nano.2017.10.007","volume":"14","author":"Z Shen","year":"2018","unstructured":"Shen Z, Li B, Liu Y, Zheng G, Guo Y, Zhao R, et al. A self-assembly nanodrug delivery system based on amphiphilic low generations of PAMAM dendrimers-ursolic acid conjugate modified by lactobionic acid for HCC targeting therapy. Nanomedicine. 2018;14(2):227\u201336.","journal-title":"Nanomedicine"},{"key":"1708_CR57","doi-asserted-by":"publisher","first-page":"115252","DOI":"10.1016\/j.carbpol.2019.115252","volume":"225","author":"X Wang","year":"2019","unstructured":"Wang X, Qi Y, Liu L, Ganbold T, Baigude H, Han J. Preparation and cell activities of lactosylated curdlan-triornithine nanoparticles for enhanced DNA\/siRNA delivery in hepatoma cells. Carbohydr Polym. 2019;225:115252.","journal-title":"Carbohydr Polym"},{"issue":"32","key":"1708_CR58","doi-asserted-by":"publisher","first-page":"4947","DOI":"10.3748\/wjg.v11.i32.4947","volume":"11","author":"XR Qi","year":"2005","unstructured":"Qi XR, Yan WW, Shi J. Hepatocytes targeting of cationic liposomes modified with soybean sterylglucoside and polyethylene glycol. World J Gastroenterol. 2005;11(32):4947\u201352.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1708_CR59","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1177\/0885328219841487","volume":"34","author":"Y Zheng","year":"2019","unstructured":"Zheng Y, Shi S, Liu Y, Zhao Y, Sun Y. Targeted pharmacokinetics of polymeric micelles modified with glycyrrhetinic acid and hydrazone bond in H22 tumor-bearing mice. J Biomater Appl. 2019;34(1):141\u201351.","journal-title":"J Biomater Appl"},{"key":"1708_CR60","doi-asserted-by":"publisher","first-page":"9437","DOI":"10.2147\/IJN.S214528","volume":"14","author":"ZP Li","year":"2019","unstructured":"Li ZP, Tian GX, Jiang H, Pan RY, Lian B, Wang M, et al. Liver-targeting and pH-sensitive sulfated hyaluronic acid mixed micelles for hepatoma therapy. Int J Nanomed. 2019;14:9437\u201352.","journal-title":"Int J Nanomed"},{"issue":"1","key":"1708_CR61","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ijpharm.2009.07.030","volume":"382","author":"KJ Longmuir","year":"2009","unstructured":"Longmuir KJ, Haynes SM, Baratta JL, Kasabwalla N, Robertson RT. Liposomal delivery of doxorubicin to hepatocytes in vivo by targeting heparan sulfate. Int J Pharm. 2009;382(1):222\u201333.","journal-title":"Int J Pharm"},{"issue":"7","key":"1708_CR62","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"A Akinc","year":"2010","unstructured":"Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther. 2010;18(7):1357\u201364.","journal-title":"Mol Ther"},{"issue":"13","key":"1708_CR63","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1096\/fasebj.6.13.1327930","volume":"6","author":"CJ Fielding","year":"1992","unstructured":"Fielding CJ. Lipoprotein receptors, plasma cholesterol metabolism, and the regulation of cellular free cholesterol concentration. FASEB J. 1992;6(13):3162\u20138.","journal-title":"FASEB J"},{"key":"1708_CR64","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.2147\/IJN.S257142","volume":"15","author":"A J\u0119drzak","year":"2020","unstructured":"J\u0119drzak A, Grze\u015bkowiak BF, Golba K, Coy E, Synoradzki K, Jurga S, et al. Magnetite nanoparticles and spheres for chemo- and photothermal therapy of hepatocellular carcinoma in vitro. Int J Nanomed. 2020;15:7923\u201336.","journal-title":"Int J Nanomed"},{"issue":"11","key":"1708_CR65","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1002\/jbm.a.36758","volume":"107","author":"N Koirala","year":"2019","unstructured":"Koirala N, Das D, Fayazzadeh E, Sen S, McClain A, Puskas JE, et al. Folic acid conjugated polymeric drug delivery vehicle for targeted cancer detection in hepatocellular carcinoma. J Biomed Mater Res A. 2019;107(11):2522\u201335.","journal-title":"J Biomed Mater Res A"},{"key":"1708_CR66","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.biomaterials.2015.07.035","volume":"67","author":"D-Y Gao","year":"2015","unstructured":"Gao D-Y, Lin T-T, Sung Y-C, Liu YC, Chiang W-H, Chang C-C, et al. CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 2015;67:194\u2013203.","journal-title":"Biomaterials"},{"key":"1708_CR67","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1016\/j.ijbiomac.2018.05.040","volume":"116","author":"P Kumari","year":"2018","unstructured":"Kumari P, Rompicharla SVK, Muddineti OS, Ghosh B, Biswas S. Transferrin-anchored poly(lactide) based micelles to improve anticancer activity of curcumin in hepatic and cervical cancer cell monolayers and 3D spheroids. Int J Biol Macromol. 2018;116:1196\u2013213.","journal-title":"Int J Biol Macromol"},{"key":"1708_CR68","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ijbiomac.2020.01.071","volume":"148","author":"H Yang","year":"2020","unstructured":"Yang H, Miao Y, Chen L, Li Z, Yang R, Xu X, et al. Redox-responsive nanoparticles from disulfide bond-linked poly-(N-\u03b5-carbobenzyloxy-l-lysine)-grafted hyaluronan copolymers as theranostic nanoparticles for tumor-targeted MRI and chemotherapy. Int J Biol Macromol. 2020;148:483\u201392.","journal-title":"Int J Biol Macromol"},{"issue":"1","key":"1708_CR69","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ijpharm.2014.08.048","volume":"475","author":"A Akhter","year":"2014","unstructured":"Akhter A, Hayashi Y, Sakurai Y, Ohga N, Hida K, Harashima H. Ligand density at the surface of a nanoparticle and different uptake mechanism: two important factors for successful siRNA delivery to liver endothelial cells. Int J Pharm. 2014;475(1):227\u201337.","journal-title":"Int J Pharm"},{"issue":"21","key":"1708_CR70","doi-asserted-by":"publisher","first-page":"11681","DOI":"10.1073\/pnas.94.21.11681","volume":"94","author":"JA Kamps","year":"1997","unstructured":"Kamps JA, Morselt HW, Swart PJ, Meijer DK, Scherphof GL. Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc Natl Acad Sci USA. 1997;94(21):11681\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"1708_CR71","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1016\/S0021-9258(18)52241-9","volume":"266","author":"TJ Van Berkel","year":"1991","unstructured":"Van Berkel TJ, De Rijke YB, Kruijt JK. Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells. J Biol Chem. 1991;266(4):2282\u20139.","journal-title":"J Biol Chem"},{"issue":"7","key":"1708_CR72","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1248\/bpb.34.1084","volume":"34","author":"N Toriyabe","year":"2011","unstructured":"Toriyabe N, Hayashi Y, Hyodo M, Harashima H. Synthesis and evaluation of stearylated hyaluronic acid for the active delivery of liposomes to liver endothelial cells. Biol Pharm Bull. 2011;34(7):1084\u20139.","journal-title":"Biol Pharm Bull"},{"issue":"4","key":"1708_CR73","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/hep.1840070410","volume":"7","author":"DP Praaning-van Dalen","year":"1987","unstructured":"Praaning-van Dalen DP, de Leeuw AM, Brouwer A, Knook DL. Rat liver endothelial cells have a greater capacity than Kupffer cells to endocytose N-acetylglucosamine- and mannose-terminated glycoproteins. Hepatology. 1987;7(4):672\u20139.","journal-title":"Hepatology"},{"issue":"2","key":"1708_CR74","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0168-8278(90)90054-U","volume":"10","author":"A Sano","year":"1990","unstructured":"Sano A, Taylor ME, Leaning MS, Summerfield JA. Uptake and processing of glycoproteins by isolated rat hepatic endothelial and kupffer cells. J Hepatol. 1990;10(2):211\u20136.","journal-title":"J Hepatol"},{"issue":"6","key":"1708_CR75","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1002\/hep.21639","volume":"45","author":"I Malovic","year":"2007","unstructured":"Malovic I, S\u00f8rensen KK, Elvevold KH, Nedredal GI, Paulsen S, Erofeev AV, et al. The mannose receptor on murine liver sinusoidal endothelial cells is the main denatured collagen clearance receptor. Hepatology. 2007;45(6):1454\u201361.","journal-title":"Hepatology"},{"issue":"12","key":"1708_CR76","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1096\/fasebj.5.12.1916092","volume":"5","author":"WH Fridman","year":"1991","unstructured":"Fridman WH. Fc receptors and immunoglobulin binding factors. FASEB J. 1991;5(12):2684\u201390.","journal-title":"FASEB J"},{"issue":"1","key":"1708_CR77","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1208\/s12249-019-1526-5","volume":"21","author":"J Zhu","year":"2019","unstructured":"Zhu J, Qin F, Ji Z, Fei W, Tan Z, Hu Y, et al. Mannose-modified PLGA nanoparticles for sustained and targeted delivery in hepatitis B virus immunoprophylaxis. AAPS PharmSciTech. 2019;21(1):13.","journal-title":"AAPS PharmSciTech"},{"issue":"7","key":"1708_CR78","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1021\/acs.molpharmaceut.8b00042","volume":"15","author":"C Lai","year":"2018","unstructured":"Lai C, Li C, Luo X, Liu M, Liu X, Hu L, et al. Use of dual-ligand modification in Kupffer cell-targeted liposomes to examine the contribution of Kupffer cells to accelerated blood clearance phenomenon. Mol Pharm. 2018;15(7):2548\u201358.","journal-title":"Mol Pharm"},{"issue":"3","key":"1708_CR79","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/j.biomaterials.2006.08.045","volume":"28","author":"Y Higuchi","year":"2007","unstructured":"Higuchi Y, Kawakami S, Yamashita F, Hashida M. The potential role of fucosylated cationic liposome\/NF\u03baB decoy complexes in the treatment of cytokine-related liver disease. Biomaterials. 2007;28(3):532\u20139.","journal-title":"Biomaterials"},{"issue":"2","key":"1708_CR80","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S0005-2736(97)00036-9","volume":"1326","author":"K Shimada","year":"1997","unstructured":"Shimada K, Kamps JAAM, Regts J, Ikeda K, Shiozawa T, Hirota S, et al. Biodistribution of liposomes containing synthetic galactose-terminated diacylglyceryl-poly(ethyleneglycol)s. Biochim Biophys Acta (BBA)\u00a0Biomembr. 1997;1326(2):329\u201341.","journal-title":"Biochim Biophys Acta (BBA)\u00a0Biomembr"},{"key":"1708_CR81","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.2147\/IJN.S192113","volume":"14","author":"A Rafique","year":"2019","unstructured":"Rafique A, Etzerodt A, Graversen JH, Moestrup SK, Dagn\u00e6s-Hansen F, M\u00f8ller HJ. Targeted lipid nanoparticle delivery of calcitriol to human monocyte-derived macrophages in vitro and in vivo: investigation of the anti-inflammatory effects of calcitriol. Int J Nanomed. 2019;14:2829\u201346.","journal-title":"Int J Nanomed"},{"issue":"8","key":"1708_CR82","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1023\/A:1025009300562","volume":"20","author":"GA Koning","year":"2003","unstructured":"Koning GA, Morselt HW, Gorter A, Allen TM, Zalipsky S, Scherphof GL, et al. Interaction of differently designed immunoliposomes with colon cancer cells and kupffer cells. An in vitro comparison. Pharm Res. 2003;20(8):1249\u201357.","journal-title":"Pharm Res"},{"issue":"5","key":"1708_CR83","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/j.cell.2005.12.039","volume":"124","author":"KY Helmy","year":"2006","unstructured":"Helmy KY, Katschke KJ Jr, Gorgani NN, Kljavin NM, Elliott JM, Diehl L, et al. CRIg: a macrophage complement receptor required for phagocytosis of circulating pathogens. Cell. 2006;124(5):915\u201327.","journal-title":"Cell"},{"issue":"3","key":"1708_CR84","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1007\/s11095-016-2081-3","volume":"34","author":"R Dutta","year":"2017","unstructured":"Dutta R, Kumar V, Peng Y, Evande RE, Grem JL, Mahato RI. Pharmacokinetics and biodistribution of GDC-0449 loaded micelles in normal and liver fibrotic mice. Pharm Res. 2017;34(3):564\u201378.","journal-title":"Pharm Res"},{"issue":"10","key":"1708_CR85","doi-asserted-by":"publisher","first-page":"1700064","DOI":"10.1002\/mabi.201700064","volume":"17","author":"T Yildirim","year":"2017","unstructured":"Yildirim T, Matth\u00e4us C, Press AT, Schubert S, Bauer M, Popp J, et al. Uptake of retinoic acid-modified PMMA nanoparticles in LX-2 and liver tissue by Raman Imaging and Intravital Microscopy. Macromol Biosci. 2017;17(10):1700064.","journal-title":"Macromol Biosci"},{"key":"1708_CR86","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2018.05.032","volume":"283","author":"JB Qiao","year":"2018","unstructured":"Qiao JB, Fan QQ, Xing L, Cui PF, He YJ, Zhu JC, et al. Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis. J Control Release. 2018;283:113\u201325.","journal-title":"J Control Release"},{"key":"1708_CR87","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.jconrel.2017.09.035","volume":"266","author":"NS El-Mezayen","year":"2017","unstructured":"El-Mezayen NS, El-Hadidy WF, El-Refaie WM, Shalaby TI, Khattab MM, El-Khatib AS. Hepatic stellate cell-targeted imatinib nanomedicine versus conventional imatinib: a novel strategy with potent efficacy in experimental liver fibrosis. J Control Release. 2017;266:226\u201337.","journal-title":"J Control Release"},{"issue":"1","key":"1708_CR88","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12951-020-00645-y","volume":"18","author":"D Ji","year":"2020","unstructured":"Ji D, Wang Q, Zhao Q, Tong H, Yu M, Wang M, et al. Co-delivery of miR-29b and germacrone based on cyclic RGD-modified nanoparticles for liver fibrosis therapy. J Nanobiotechnol. 2020;18(1):86.","journal-title":"J Nanobiotechnol"},{"key":"1708_CR89","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejps.2013.11.017","volume":"52","author":"J Yang","year":"2014","unstructured":"Yang J, Hou Y, Ji G, Song Z, Liu Y, Dai G, et al. Targeted delivery of the RGD-labeled biodegradable polymersomes loaded with the hydrophilic drug oxymatrine on cultured hepatic stellate cells and liver fibrosis in rats. Eur J Pharm Sci. 2014;52:180\u201390.","journal-title":"Eur J Pharm Sci"},{"key":"1708_CR90","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jconrel.2017.11.029","volume":"269","author":"F van Dijk","year":"2018","unstructured":"van Dijk F, Teekamp N, Beljaars L, Post E, Zuidema J, Steendam R, et al. Pharmacokinetics of a sustained release formulation of PDGF\u03b2-receptor directed carrier proteins to target the fibrotic liver. J Control Release. 2018;269:258\u201365.","journal-title":"J Control Release"},{"key":"1708_CR91","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.jconrel.2018.12.039","volume":"296","author":"F van Dijk","year":"2019","unstructured":"van Dijk F, Teekamp N, Post E, Schuppan D, Kim YO, Zuidema J, et al. The antifibrotic potential of a sustained release formulation of a PDGF\u03b2-receptor targeted rho kinase inhibitor. J Control Release. 2019;296:250\u20137.","journal-title":"J Control Release"},{"issue":"3","key":"1708_CR92","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jhep.2005.08.027","volume":"44","author":"JE Adrian","year":"2006","unstructured":"Adrian JE, Poelstra K, Scherphof GL, Molema G, Meijer DK, Reker-Smit C, et al. Interaction of targeted liposomes with primary cultured hepatic stellate cells: involvement of multiple receptor systems. J Hepatol. 2006;44(3):560\u20137.","journal-title":"J Hepatol"},{"issue":"5","key":"1708_CR93","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nri.2017.11","volume":"17","author":"O Krenkel","year":"2017","unstructured":"Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017;17(5):306\u201321.","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"1708_CR94","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.jhep.2019.02.012","volume":"70","author":"A Hammoutene","year":"2019","unstructured":"Hammoutene A, Rautou PE. Role of liver sinusoidal endothelial cells in non-alcoholic fatty liver disease. J Hepatol. 2019;70(6):1278\u201391.","journal-title":"J Hepatol"},{"issue":"5","key":"1708_CR95","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1172\/JCI66369","volume":"123","author":"C Yin","year":"2013","unstructured":"Yin C, Evason KJ, Asahina K, Stainier DY. Hepatic stellate cells in liver development, regeneration, and cancer. J Clin Invest. 2013;123(5):1902\u201310.","journal-title":"J Clin Invest"},{"issue":"4","key":"1708_CR96","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jhep.2015.06.015","volume":"63","author":"P Gissen","year":"2015","unstructured":"Gissen P, Arias IM. Structural and functional hepatocyte polarity and liver disease. J Hepatol. 2015;63(4):1023\u201337.","journal-title":"J Hepatol"},{"issue":"4","key":"1708_CR97","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.carbpol.2012.04.056","volume":"89","author":"R Subbiah","year":"2012","unstructured":"Subbiah R, Ramalingam P, Ramasundaram S, Kim DY, Park K, Ramasamy MK, et al. N,N,N-Trimethyl chitosan nanoparticles for controlled intranasal delivery of HBV surface antigen. Carbohydr Polym. 2012;89(4):1289\u201397.","journal-title":"Carbohydr Polym"},{"issue":"1\u20132","key":"1708_CR98","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ijpharm.2011.05.053","volume":"415","author":"P Zeng","year":"2011","unstructured":"Zeng P, Xu Y, Zeng C, Ren H, Peng M. Chitosan-modified poly(D,L-lactide-co-glycolide) nanospheres for plasmid DNA delivery and HBV gene-silencing. Int J Pharm. 2011;415(1\u20132):259\u201366.","journal-title":"Int J Pharm"},{"issue":"2","key":"1708_CR99","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ijpharm.2015.08.056","volume":"495","author":"M Xue","year":"2015","unstructured":"Xue M, Hu S, Lu Y, Zhang Y, Jiang X, An S, et al. Development of chitosan nanoparticles as drug delivery system for a prototype capsid inhibitor. Int J Pharm. 2015;495(2):771\u201382.","journal-title":"Int J Pharm"},{"key":"1708_CR100","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.carbpol.2019.02.047","volume":"212","author":"J Miao","year":"2019","unstructured":"Miao J, Yang XQ, Gao Z, Li Q, Meng TT, Wu JY, et al. Redox-responsive chitosan oligosaccharide-SS-Octadecylamine polymeric carrier for efficient anti-hepatitis B virus gene therapy. Carbohydr Polym. 2019;212:215\u201321.","journal-title":"Carbohydr Polym"},{"key":"1708_CR101","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.ejpb.2017.12.003","volume":"124","author":"H Wang","year":"2018","unstructured":"Wang H, Han Q, Zhao H, Xu D, Zhang J. Single dose HBsAg CS-\u03b3-PGA nanogels induce potent protective immune responses against HBV infection. Eur J Pharm Biopharm. 2018;124:82\u20138.","journal-title":"Eur J Pharm Biopharm"},{"key":"1708_CR102","doi-asserted-by":"publisher","first-page":"407","DOI":"10.3389\/fchem.2020.00407","volume":"8","author":"R Zhao","year":"2020","unstructured":"Zhao R, Zhu M, Zhou S, Feng W, Chen H. Rapamycin-loaded mPEG-PLGA nanoparticles ameliorate hepatic steatosis and liver injury in non-alcoholic fatty liver disease. Front Chem. 2020;8:407.","journal-title":"Front Chem"},{"issue":"5","key":"1708_CR103","doi-asserted-by":"publisher","first-page":"4842","DOI":"10.1021\/acsami.8b19717","volume":"11","author":"W Zai","year":"2019","unstructured":"Zai W, Chen W, Wu Z, Jin X, Fan J, Zhang X, et al. Targeted interleukin-22 gene delivery in the liver by Polymetformin and Penetratin-Based hybrid nanoparticles to treat nonalcoholic fatty liver disease. ACS Appl Mater Interfaces. 2019;11(5):4842\u201357.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1708_CR104","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2019.06.023","volume":"307","author":"W Teng","year":"2019","unstructured":"Teng W, Zhao L, Yang S, Zhang C, Liu M, Luo J, et al. The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease. J Control Release. 2019;307:139\u201349.","journal-title":"J Control Release"},{"key":"1708_CR105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.biomaterials.2019.01.008","volume":"197","author":"S Lee","year":"2019","unstructured":"Lee S, Han D, Kang HG, Jeong SJ, Jo JE, Shin J, et al. Intravenous sustained-release nifedipine ameliorates nonalcoholic fatty liver disease by restoring autophagic clearance. Biomaterials. 2019;197:1\u201311.","journal-title":"Biomaterials"},{"issue":"11","key":"1708_CR106","doi-asserted-by":"publisher","first-page":"181457","DOI":"10.1098\/rsos.181457","volume":"5","author":"SQ Wan","year":"2018","unstructured":"Wan SQ, Zhang L, Quan YY, Wei K. Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy. R Soc Open Sci. 2018;5(11):181457.","journal-title":"R Soc Open Sci"},{"key":"1708_CR107","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.jconrel.2018.09.004","volume":"288","author":"DW Kurniawan","year":"2018","unstructured":"Kurniawan DW, Jajoriya AK, Dhawan G, Mishra D, Argemi J, Bataller R, et al. Therapeutic inhibition of spleen tyrosine kinase in inflammatory macrophages using PLGA nanoparticles for the treatment of non-alcoholic steatohepatitis. J Control Release. 2018;288:227\u201338.","journal-title":"J Control Release"},{"issue":"sup2","key":"1708_CR108","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/21691401.2018.1453830","volume":"46","author":"S He","year":"2018","unstructured":"He S, Guo W, Deng F, Chen K, Jiang Y, Dong M, et al. Targeted delivery of microRNA 146b mimic to hepatocytes by lactosylated PDMAEMA nanoparticles for the treatment of NAFLD. Artif Cells Nanomed Biotechnol. 2018;46(sup2):217\u201328.","journal-title":"Artif Cells Nanomed Biotechnol"},{"issue":"10","key":"1708_CR109","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1021\/acs.molpharmaceut.8b00548","volume":"15","author":"YN Cao","year":"2018","unstructured":"Cao YN, Baiyisaiti A, Wong CW, Hsu SH, Qi R. Polyurethane nanoparticle-loaded fenofibrate exerts inhibitory effects on nonalcoholic fatty liver disease in mice. Mol Pharm. 2018;15(10):4550\u20137.","journal-title":"Mol Pharm"},{"issue":"8","key":"1708_CR110","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1139\/cjpp-2019-0141","volume":"97","author":"F Shafie","year":"2019","unstructured":"Shafie F, Nabavizadeh F, Shafie Ardestani M, Panahi M, Adeli S, Samandari H, et al. Sorafenib-loaded PAMAM dendrimer attenuates liver fibrosis and its complications in bile-duct-ligated rats. Can J Physiol Pharmacol. 2019;97(8):691\u20138.","journal-title":"Can J Physiol Pharmacol"},{"key":"1708_CR111","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.jddst.2019.03.019","volume":"51","author":"R Krithika","year":"2019","unstructured":"Krithika R, Vhora I, Verma RJ. Preparation, toxicity analysis and in vivo protective effect of phyllanthin-loaded PLGA nanoparticles against CCl4-induced hepatic fibrosis. J Drug Deliv Sci Technol. 2019;51:364\u201371.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1708_CR112","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ejpb.2018.11.018","volume":"134","author":"R Hassan","year":"2019","unstructured":"Hassan R, Tammam SN, Safy SE, Abdel-Halim M, Asimakopoulou A, Weiskirchen R, et al. Prevention of hepatic stellate cell activation using JQ1- and atorvastatin-loaded chitosan nanoparticles as a promising approach in therapy of liver fibrosis. Eur J Pharm Biopharm. 2019;134:96\u2013106.","journal-title":"Eur J Pharm Biopharm"},{"key":"1708_CR113","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.ejpb.2020.01.003","volume":"148","author":"S El-Safy","year":"2020","unstructured":"El-Safy S, Tammam SN, Abdel-Halim M, Ali ME, Youshia J, Shetab Boushehri MA, et al. Collagenase loaded chitosan nanoparticles for digestion of the collagenous scar in liver fibrosis: the effect of chitosan intrinsic collagen binding on the success of targeting. Eur J Pharm Biopharm. 2020;148:54\u201366.","journal-title":"Eur J Pharm Biopharm"},{"issue":"5\u20136","key":"1708_CR114","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1080\/1061186X.2017.1419358","volume":"26","author":"CC Chang","year":"2018","unstructured":"Chang CC, Yang Y, Gao DY, Cheng HT, Hoang B, Chao PH, et al. Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl(4)-induced hepatic fibrosis in mice. J Drug Target. 2018;26(5\u20136):516\u201324.","journal-title":"J Drug Target"},{"key":"1708_CR115","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.biopha.2016.03.042","volume":"81","author":"N Younis","year":"2016","unstructured":"Younis N, Shaheen MA, Abdallah MH. Silymarin-loaded Eudragit(\u00ae) RS100 nanoparticles improved the ability of silymarin to resolve hepatic fibrosis in bile duct ligated rats. Biomed Pharmacother. 2016;81:93\u2013103.","journal-title":"Biomed Pharmacother"},{"issue":"12","key":"1708_CR116","doi-asserted-by":"publisher","first-page":"e0145512","DOI":"10.1371\/journal.pone.0145512","volume":"10","author":"RG Thomas","year":"2015","unstructured":"Thomas RG, Moon MJ, Kim JH, Lee JH, Jeong YY. Effectiveness of losartan-loaded hyaluronic acid (HA) Micelles for the reduction of advanced hepatic fibrosis in C3H\/HeN mice model. PLoS ONE. 2015;10(12):e0145512.","journal-title":"PLoS ONE"},{"issue":"9","key":"1708_CR117","doi-asserted-by":"publisher","first-page":"6452","DOI":"10.1166\/jnn.2015.10608","volume":"15","author":"AM Safer","year":"2015","unstructured":"Safer AM, Hanafy NA, Bharali DJ, Cui H, Mousa SA. Effect of green tea extract encapsulated into chitosan nanoparticles on hepatic fibrosis collagen fibers assessed by Atomic Force Microscopy in rat hepatic fibrosis model. J Nanosci Nanotechnol. 2015;15(9):6452\u20139.","journal-title":"J Nanosci Nanotechnol"},{"issue":"18","key":"1708_CR118","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1002\/adhm.201500826","volume":"4","author":"L Kaps","year":"2015","unstructured":"Kaps L, Nuhn L, Aslam M, Brose A, Foerster F, Rosigkeit S, et al. In vivo gene-silencing in fibrotic liver by siRNA-loaded cationic nanohydrogel particles. Adv Healthc Mater. 2015;4(18):2809\u201315.","journal-title":"Adv Healthc Mater"},{"issue":"4","key":"1708_CR119","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1208\/s12249-020-01655-7","volume":"21","author":"X Nie","year":"2020","unstructured":"Nie X, Liu Y, Li M, Yu X, Yuan W, Huang S, et al. SP94 peptide-functionalized PEG-PLGA nanoparticle loading with cryptotanshinone for targeting therapy of hepatocellular carcinoma. AAPS PharmSciTech. 2020;21(4):124.","journal-title":"AAPS PharmSciTech"},{"key":"1708_CR120","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.2147\/IJN.S237335","volume":"15","author":"Z Li","year":"2020","unstructured":"Li Z, Ye L, Liu J, Lian D, Li X. Sorafenib-loaded nanoparticles based on biodegradable dendritic polymers for enhanced therapy of hepatocellular carcinoma. Int J Nanomed. 2020;15:1469\u201380.","journal-title":"Int J Nanomed"},{"issue":"4","key":"1708_CR121","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1080\/08982104.2019.1570250","volume":"29","author":"J Varshosaz","year":"2019","unstructured":"Varshosaz J, Raghami F, Rostami M, Jahanian A. PEGylated trimethylchitosan emulsomes conjugated to octreotide for targeted delivery of sorafenib to hepatocellular carcinoma cells of HepG2. J Liposome Res. 2019;29(4):383\u201398.","journal-title":"J Liposome Res"},{"key":"1708_CR122","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.ijbiomac.2019.07.225","volume":"139","author":"J Varshosaz","year":"2019","unstructured":"Varshosaz J, Sadri F, Rostami M, Mirian M, Taymouri S. Synthesis of pectin-deoxycholic acid conjugate for targeted delivery of anticancer drugs in hepatocellular carcinoma. Int J Biol Macromol. 2019;139:665\u201377.","journal-title":"Int J Biol Macromol"},{"issue":"2","key":"1708_CR123","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41388-018-0406-x","volume":"38","author":"R Toshiyama","year":"2019","unstructured":"Toshiyama R, Konno M, Eguchi H, Takemoto H, Noda T, Asai A, et al. Poly(ethylene glycol)-poly(lysine) block copolymer-ubenimex conjugate targets aminopeptidase N and exerts an antitumor effect in hepatocellular carcinoma stem cells. Oncogene. 2019;38(2):244\u201360.","journal-title":"Oncogene"},{"key":"1708_CR124","doi-asserted-by":"publisher","first-page":"108691","DOI":"10.1016\/j.biopha.2019.108691","volume":"112","author":"S Patil","year":"2019","unstructured":"Patil S, Ujalambkar V, Rathore A, Rojatkar S, Pokharkar V. Galangin loaded galactosylated pluronic F68 polymeric micelles for liver targeting. Biomed Pharmacother. 2019;112:108691.","journal-title":"Biomed Pharmacother"},{"key":"1708_CR125","doi-asserted-by":"publisher","first-page":"110413","DOI":"10.1016\/j.colsurfb.2019.110413","volume":"183","author":"Y Huang","year":"2019","unstructured":"Huang Y, Xu Y, Wu Y, Chen T, Lu W, Yu J. Bioinspired nanoplatform for enhanced delivery efficiency of doxorubicin into nucleus with fast endocytosis, lysosomal pH-triggered drug release, and reduced efflux. Colloids Surf B Biointerfaces. 2019;183:110413.","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"8","key":"1708_CR126","doi-asserted-by":"publisher","first-page":"849","DOI":"10.2217\/nnm-2017-0306","volume":"13","author":"P Pandey","year":"2018","unstructured":"Pandey P, Rahman M, Bhatt PC, Beg S, Paul B, Hafeez A, et al. Implication of nano-antioxidant therapy for treatment of hepatocellular carcinoma using PLGA nanoparticles of rutin. Nanomedicine (Lond). 2018;13(8):849\u201370.","journal-title":"Nanomedicine (Lond)"},{"key":"1708_CR127","doi-asserted-by":"publisher","first-page":"4367","DOI":"10.2147\/IJN.S81413","volume":"10","author":"F Hu","year":"2015","unstructured":"Hu F, Wang H, Zhang S, Peng Y, Su L, Chang J, et al. Inhibition of myeloid differentiation factor 88 signaling mediated by histidine-grafted poly(\u03b2-amino ester) ester nanovector induces donor-specific liver allograft tolerance. Int J Nanomed. 2015;10:4367\u201382.","journal-title":"Int J Nanomed"},{"issue":"10","key":"1708_CR128","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1111\/jphp.12430","volume":"67","author":"NP Mistry","year":"2015","unstructured":"Mistry NP, Desai JL, Thakkar HP. Formulation and evaluation of tacrolimus-loaded galactosylated poly(lactic-co-glycolic acid) nanoparticles for liver targeting. J Pharm Pharmacol. 2015;67(10):1337\u201348.","journal-title":"J Pharm Pharmacol"},{"issue":"6","key":"1708_CR129","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1016\/j.celrep.2016.04.007","volume":"15","author":"J Azzi","year":"2016","unstructured":"Azzi J, Yin Q, Uehara M, Ohori S, Tang L, Cai K, et al. Targeted delivery of immunomodulators to lymph nodes. Cell Rep. 2016;15(6):1202\u201313.","journal-title":"Cell Rep"},{"issue":"10","key":"1708_CR130","doi-asserted-by":"publisher","first-page":"18262","DOI":"10.1002\/jcp.28458","volume":"234","author":"A Mansouri","year":"2019","unstructured":"Mansouri A, Abnous K, Alibolandi M, Taghdisi SM, Ramezani M. Targeted delivery of tacrolimus to T cells by pH-responsive aptamer-chitosan- poly(lactic-co-glycolic acid) nanocomplex. J Cell Physiol. 2019;234(10):18262\u201371.","journal-title":"J Cell Physiol"},{"issue":"11","key":"1708_CR131","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/S2468-1253(19)30190-6","volume":"4","author":"T Asselah","year":"2019","unstructured":"Asselah T, Loureiro D, Boyer N, Mansouri A. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. Lancet Gastroenterol Hepatol. 2019;4(11):883\u201392.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1\u20132","key":"1708_CR132","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ijpharm.2016.03.013","volume":"504","author":"S Jesus","year":"2016","unstructured":"Jesus S, Soares E, Costa J, Borchard G, Borges O. Immune response elicited by an intranasally delivered HBsAg low-dose adsorbed to poly-\u03b5-caprolactone based nanoparticles. Int J Pharm. 2016;504(1\u20132):59\u201369.","journal-title":"Int J Pharm"},{"key":"1708_CR133","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1016\/j.ijbiomac.2018.01.073","volume":"111","author":"HK Dewangan","year":"2018","unstructured":"Dewangan HK, Pandey T, Maurya L, Singh S. Rational design and evaluation of HBsAg polymeric nanoparticles as antigen delivery carriers. Int J Biol Macromol. 2018;111:804\u201312.","journal-title":"Int J Biol Macromol"},{"issue":"8","key":"1708_CR134","first-page":"2033","volume":"46","author":"HK Dewangan","year":"2018","unstructured":"Dewangan HK, Pandey T, Singh S. Nanovaccine for immunotherapy and reduced hepatitis-B virus in humanized model. Artif Cells Nanomed Biotechnol. 2018;46(8):2033\u201342.","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"1708_CR135","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cis.2019.03.007","volume":"268","author":"D Chuan","year":"2019","unstructured":"Chuan D, Jin T, Fan R, Zhou L, Guo G. Chitosan for gene delivery: methods for improvement and applications. Adv Colloid Interface Sci. 2019;268:25\u201338.","journal-title":"Adv Colloid Interface Sci"},{"issue":"12","key":"1708_CR136","doi-asserted-by":"publisher","first-page":"28230","DOI":"10.3390\/ijms161226094","volume":"16","author":"B Ndeboko","year":"2015","unstructured":"Ndeboko B, Lemamy GJ, Nielsen PE, Cova L. Therapeutic potential of cell penetrating peptides (CPPs) and cationic polymers for chronic hepatitis B. Int J Mol Sci. 2015;16(12):28230\u201341.","journal-title":"Int J Mol Sci"},{"key":"1708_CR137","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ejps.2018.03.016","volume":"118","author":"MM Ayoub","year":"2018","unstructured":"Ayoub MM, Elantouny NG, El-Nahas HM, Ghazy FES. Injectable PLGA Adefovir microspheres; the way for long term therapy of chronic hepatitis-B. Eur J Pharm Sci. 2018;118:24\u201331.","journal-title":"Eur J Pharm Sci"},{"key":"1708_CR138","doi-asserted-by":"publisher","first-page":"101585","DOI":"10.1016\/j.jddst.2020.101585","volume":"56","author":"MM Ayoub","year":"2020","unstructured":"Ayoub MM, Jasti B, Elantouny NG, Elnahas H, Ghazy FE. Comparative study of PLGA in-situ implant and nanoparticle formulations of entecavir; in-vitro and in-vivo evaluation. J Drug Deliv Sci Technol. 2020;56:101585.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1708_CR139","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijpharm.2019.01.052","volume":"560","author":"C Zhang","year":"2019","unstructured":"Zhang C, Wang A, Wang H, Yan M, Liang R, He X, et al. Entecavir-loaded poly (lactic-co-glycolic acid) microspheres for long-term therapy of chronic hepatitis-B: preparation and in vitro and in vivo evaluation. Int J Pharm. 2019;560:27\u201334.","journal-title":"Int J Pharm"},{"issue":"1","key":"1708_CR140","doi-asserted-by":"publisher","first-page":"e0227231","DOI":"10.1371\/journal.pone.0227231","volume":"15","author":"M Hamdi","year":"2020","unstructured":"Hamdi M, Abdel-Bar HM, Elmowafy E, Al-Jamal KT, Awad GAS. An integrated vitamin E-coated polymer hybrid nanoplatform: a lucrative option for an enhanced in vitro macrophage retention for an anti-hepatitis B therapeutic prospect. PLoS ONE. 2020;15(1):e0227231.","journal-title":"PLoS ONE"},{"key":"1708_CR141","doi-asserted-by":"publisher","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","volume":"1","author":"EM Brunt","year":"2015","unstructured":"Brunt EM, Wong VW, Nobili V, Day CP, Sookoian S, Maher JJ, et al. Nonalcoholic fatty liver disease. Nat Rev Dis Primers. 2015;1:15080.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"1708_CR142","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","volume":"24","author":"SL Friedman","year":"2018","unstructured":"Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908\u201322.","journal-title":"Nat Med"},{"issue":"9","key":"1708_CR143","first-page":"65","volume":"169","author":"XJ Wang","year":"2018","unstructured":"Wang XJ, Malhi H. Nonalcoholic fatty liver disease. Ann Intern Med. 2018;169(9):65\u201380.","journal-title":"Ann Intern Med"},{"issue":"6","key":"1708_CR144","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1053\/j.gastro.2017.01.015","volume":"152","author":"C Alonso","year":"2017","unstructured":"Alonso C, Fern\u00e1ndez-Ramos D, Varela-Rey M, Mart\u00ednez-Arranz I, Navasa N, Van Liempd SM, et al. Metabolomic identification subtypes nonalcoholic steatohepatitis. \u00a0Gastroenterology. 2017;152(6):1449\u201361.","journal-title":"\u00a0Gastroenterology"},{"issue":"4","key":"1708_CR145","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","volume":"142","author":"K Cusi","year":"2012","unstructured":"Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711\u201325.","journal-title":"Gastroenterology"},{"issue":"2","key":"1708_CR146","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1002\/hep.23719","volume":"52","author":"BA Neuschwander-Tetri","year":"2010","unstructured":"Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology. 2010;52(2):774\u201388.","journal-title":"Hepatology"},{"issue":"1","key":"1708_CR147","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.29367","volume":"67","author":"N Chalasani","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the study of Liver Diseases. Hepatology. 2018;67(1):328\u201357.","journal-title":"Hepatology"},{"issue":"1","key":"1708_CR148","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s12951-018-0391-9","volume":"16","author":"J Liang","year":"2018","unstructured":"Liang J, Liu Y, Liu J, Li Z, Fan Q, Jiang Z, et al. Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD. J Nanobiotechnol. 2018;16(1):64.","journal-title":"J Nanobiotechnol"},{"issue":"Suppl 1","key":"1708_CR149","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/liv.13682","volume":"38","author":"P Marcellin","year":"2018","unstructured":"Marcellin P, Kutala BK. Liver diseases: a major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018;38(Suppl 1):2\u20136.","journal-title":"Liver Int"},{"issue":"5","key":"1708_CR150","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","volume":"64","author":"YA Lee","year":"2015","unstructured":"Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64(5):830\u201341.","journal-title":"Gut"},{"issue":"1","key":"1708_CR151","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1755-1536-1-5","volume":"1","author":"E Novo","year":"2008","unstructured":"Novo E, Parola M. Redox mechanisms in hepatic chronic wound healing and fibrogenesis. Fibrogenesis Tissue Repair. 2008;1(1):5.","journal-title":"Fibrogenesis Tissue Repair"},{"key":"1708_CR152","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.abb.2014.02.015","volume":"548","author":"E Novo","year":"2014","unstructured":"Novo E, Cannito S, Paternostro C, Bocca C, Miglietta A, Parola M. Cellular and molecular mechanisms in liver fibrogenesis. Arch Biochem Biophys. 2014;548:20\u201337.","journal-title":"Arch Biochem Biophys"},{"key":"1708_CR153","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mam.2018.09.002","volume":"65","author":"M Parola","year":"2019","unstructured":"Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37\u201355.","journal-title":"Mol Aspects Med"},{"issue":"7","key":"1708_CR154","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/j.bbadis.2012.11.002","volume":"1832","author":"JP Iredale","year":"2013","unstructured":"Iredale JP, Thompson A, Henderson NC. Extracellular matrix degradation in liver fibrosis: biochemistry and regulation. Biochim Biophys Acta. 2013;1832(7):876\u201383.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"1708_CR155","doi-asserted-by":"publisher","first-page":"132","DOI":"10.3109\/07388551.2014.930017","volume":"36","author":"JH Kang","year":"2016","unstructured":"Kang JH, Toita R, Murata M. Liver cell-targeted delivery of therapeutic molecules. Crit Rev Biotechnol. 2016;36(1):132\u201343.","journal-title":"Crit Rev Biotechnol"},{"issue":"7","key":"1708_CR156","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.apsb.2020.03.007","volume":"10","author":"S Mahdinloo","year":"2020","unstructured":"Mahdinloo S, Kiaie SH, Amiri A, Hemmati S, Valizadeh H, Zakeri-Milani P. Efficient drug and gene delivery to liver fibrosis: rationale, recent advances, and perspectives. Acta Pharm Sinica B. 2020;10(7):1279\u201393.","journal-title":"Acta Pharm Sinica B"},{"issue":"5","key":"1708_CR157","first-page":"1645","volume":"23","author":"R Rohilla","year":"2016","unstructured":"Rohilla R, Garg T, Goyal AK, Rath G. Herbal and polymeric approaches for liver-targeting drug delivery: novel strategies and their significance. Drug Deliv. 2016;23(5):1645\u201361.","journal-title":"Drug Deliv"},{"issue":"4","key":"1708_CR158","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.cld.2008.07.011","volume":"12","author":"DC Rockey","year":"2008","unstructured":"Rockey DC. Current and future anti-fibrotic therapies for chronic liver disease. Clin Liver Dis. 2008;12(4):939\u201362.","journal-title":"Clin Liver Dis"},{"issue":"1","key":"1708_CR159","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1055\/s-0036-1571295","volume":"36","author":"YJ Yoon","year":"2016","unstructured":"Yoon YJ, Friedman SL, Lee YA. Antifibrotic therapies: where are we now? Semin Liver Dis. 2016;36(1):87\u201398.","journal-title":"Semin Liver Dis"},{"issue":"3","key":"1708_CR160","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jtcme.2017.07.002","volume":"8","author":"U Latief","year":"2018","unstructured":"Latief U, Ahmad R. Herbal remedies for liver fibrosis: a review on the mode of action of fifty herbs. J Tradit Complement Med. 2018;8(3):352\u201360.","journal-title":"J Tradit Complement Med"},{"issue":"4","key":"1708_CR161","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/j.apsb.2019.07.003","volume":"10","author":"W Li","year":"2020","unstructured":"Li W, Zhou C, Fu Y, Chen T, Liu X, Zhang Z, et al. Targeted delivery of hyaluronic acid nanomicelles to hepatic stellate cells in hepatic fibrosis rats. Acta Pharm Sin B. 2020;10(4):693\u2013710.","journal-title":"Acta Pharm Sin B"},{"issue":"7","key":"1708_CR162","doi-asserted-by":"publisher","first-page":"1903138","DOI":"10.1002\/advs.201903138","volume":"7","author":"L Lin","year":"2020","unstructured":"Lin L, Gong H, Li R, Huang J, Cai M, Lan T, et al. Nanodrug with ROS and pH dual-sensitivity ameliorates liver fibrosis via multicellular regulation. Adv Sci (Weinh). 2020;7(7):1903138.","journal-title":"Adv Sci (Weinh)"},{"key":"1708_CR163","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.ijbiomac.2020.02.170","volume":"151","author":"Q Hu","year":"2020","unstructured":"Hu Q, Hu S, Fleming E, Lee JY, Luo Y. Chitosan-caseinate-dextran ternary complex nanoparticles for potential oral delivery of astaxanthin with significantly improved bioactivity. Int J Biol Macromol. 2020;151:747\u201356.","journal-title":"Int J Biol Macromol"},{"key":"1708_CR164","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jconrel.2015.11.003","volume":"221","author":"TT Lin","year":"2016","unstructured":"Lin TT, Gao DY, Liu YC, Sung YC, Wan DH, Liu JY, et al. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. J Controlled Release. 2016;221:62\u201370.","journal-title":"J Controlled Release"},{"key":"1708_CR165","doi-asserted-by":"publisher","first-page":"119616","DOI":"10.1016\/j.biomaterials.2019.119616","volume":"230","author":"QQ Fan","year":"2020","unstructured":"Fan QQ, Zhang CL, Qiao JB, Cui PF, Xing L, Oh YK, et al. Extracellular matrix-penetrating nanodrill micelles for liver fibrosis therapy. Biomaterials. 2020;230:119616.","journal-title":"Biomaterials"},{"issue":"5","key":"1708_CR166","doi-asserted-by":"publisher","first-page":"1801809","DOI":"10.1002\/advs.201801809","volume":"6","author":"J Wu","year":"2019","unstructured":"Wu J, Huang J, Kuang S, Chen J, Li X, Chen B, et al. Synergistic MicroRNA therapy in liver fibrotic rat using MRI-Visible nanocarrier targeting hepatic stellate cells. Adv Sci (Weinh). 2019;6(5):1801809.","journal-title":"Adv Sci (Weinh)"},{"key":"1708_CR167","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jconrel.2016.12.006","volume":"248","author":"N Leber","year":"2017","unstructured":"Leber N, Kaps L, Aslam M, Schupp J, Brose A, Sch\u00e4ffel D, et al. SiRNA-mediated in vivo gene knockdown by acid-degradable cationic nanohydrogel particles. J Control Release. 2017;248:10\u201323.","journal-title":"J Control Release"},{"issue":"3","key":"1708_CR168","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1021\/nn505166x","volume":"9","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Wang C, Zha Y, Hu W, Gao Z, Zang Y, et al. Corona-directed nucleic acid delivery into hepatic stellate cells for liver fibrosis therapy. ACS Nano. 2015;9(3):2405\u201319.","journal-title":"ACS Nano"},{"issue":"15","key":"1708_CR169","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1056\/NEJMra1713263","volume":"380","author":"A Villanueva","year":"2019","unstructured":"Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450\u201362.","journal-title":"N Engl J Med"},{"issue":"4","key":"1708_CR170","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao YM, El-Serag HB. Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 2017;153(4):996\u20131005.","journal-title":"Gastroenterology"},{"issue":"2","key":"1708_CR171","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/jhep.2003.50047","volume":"37","author":"JM Llovet","year":"2003","unstructured":"Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429\u201342.","journal-title":"Hepatology"},{"key":"1708_CR172","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.semcancer.2019.08.016","volume":"69","author":"MH Elnaggar","year":"2021","unstructured":"Elnaggar MH, Abushouk AI, Hassan AHE, Lamloum HM, Benmelouka A, Moatamed SA, et al. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma. Semin Cancer Biol. 2021;69:91\u20139.","journal-title":"Semin Cancer Biol"},{"key":"1708_CR173","doi-asserted-by":"publisher","first-page":"119250","DOI":"10.1016\/j.ijpharm.2020.119250","volume":"580","author":"Y Huang","year":"2020","unstructured":"Huang Y, Zhang W, Xu Y, Zhu S, Wu Y, Chen T, et al. Dynamic core crosslinked camptothecin prodrug micelles with reduction sensitivity and boronic acid-mediated enhanced endocytosis: an intelligent tumor-targeted delivery nanoplatform. Int J Pharm. 2020;580:119250.","journal-title":"Int J Pharm"},{"issue":"1","key":"1708_CR174","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1080\/10717544.2018.1461957","volume":"25","author":"DH Yang","year":"2018","unstructured":"Yang DH, Kim HJ, Park K, Kim JK, Chun HJ. Preparation of poly-l-lysine-based nanoparticles with pH-sensitive release of curcumin for targeted imaging and therapy of liver cancer in vitro and in vivo. Drug Deliv. 2018;25(1):950\u201360.","journal-title":"Drug Deliv"},{"key":"1708_CR175","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.2147\/IJN.S193170","volume":"14","author":"T Yang","year":"2019","unstructured":"Yang T, Du G, Cui Y, Yu R, Hua C, Tian W, et al. pH-sensitive doxorubicin-loaded polymeric nanocomplex based on \u03b2-cyclodextrin for liver cancer-targeted therapy. Int J Nanomed. 2019;14:1997\u20132010.","journal-title":"Int J Nanomed"},{"key":"1708_CR176","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jconrel.2017.11.031","volume":"269","author":"D Yang","year":"2018","unstructured":"Yang D, Luo W, Wang J, Zheng M, Liao XH, Zhang N, et al. A novel controlled release formulation of the Pin1 inhibitor ATRA to improve liver cancer therapy by simultaneously blocking multiple cancer pathways. J Control Release. 2018;269:405\u201322.","journal-title":"J Control Release"},{"key":"1708_CR177","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.msec.2018.05.011","volume":"91","author":"H Gan","year":"2018","unstructured":"Gan H, Chen L, Sui X, Wu B, Zou S, Li A, et al. Enhanced delivery of sorafenib with anti-GPC3 antibody-conjugated TPGS-b-PCL\/Pluronic P123 polymeric nanoparticles for targeted therapy of hepatocellular carcinoma. Mater Sci Eng C Mater Biol Appl. 2018;91:395\u2013403.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"1708_CR178","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcis.2019.05.008","volume":"551","author":"J Wang","year":"2019","unstructured":"Wang J, Xia Y, Liu H, Xia J, Qian M, Zhang L, et al. Poly(lactobionamidoethyl methacrylate)-based amphiphiles with ultrasound-labile components in manufacture of drug delivery nanoparticulates for augmented cytotoxic efficacy to hepatocellular carcinoma. J Colloid Interface Sci. 2019;551:1\u20139.","journal-title":"J Colloid Interface Sci"},{"key":"1708_CR179","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.msec.2018.02.013","volume":"87","author":"T Yan","year":"2018","unstructured":"Yan T, Cheng J, Liu Z, Cheng F, Wei X, Huang Y, et al. Acid-sensitive polymeric vector targeting to hepatocarcinoma cells via glycyrrhetinic acid receptor-mediated endocytosis. Mater Sci Eng C Mater Biol Appl. 2018;87:32\u201340.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"2","key":"1708_CR180","first-page":"541","volume":"17","author":"H Guo","year":"2020","unstructured":"Guo H, Xu M, Cao Z, Li W, Chen L, Xie X, et al. Ultrasound-assisted mir-122-loaded polymeric nanodroplets for hepatocellular carcinoma gene therapy. Mol Pharm. 2020;17(2):541\u201353.","journal-title":"Mol Pharm"},{"issue":"8","key":"1708_CR181","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1039\/C9BM00394K","volume":"7","author":"J Yang","year":"2019","unstructured":"Yang J, Zhang J, Liu Y, Shi Z, Han H, Li Q. Phenylboronic acid-modified polyamidoamine-mediated delivery of short GC rich DNA for hepatocarcinoma gene therapy. Biomater Sci. 2019;7(8):3348\u201358.","journal-title":"Biomater Sci"},{"key":"1708_CR182","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.biomaterials.2018.08.064","volume":"184","author":"L Liu","year":"2018","unstructured":"Liu L, Zong ZM, Liu Q, Jiang SS, Zhang Q, Cen LQ, et al. A novel galactose-PEG-conjugated biodegradable copolymer is an efficient gene delivery vector for immunotherapy of hepatocellular carcinoma. Biomaterials. 2018;184:20\u201330.","journal-title":"Biomaterials"},{"issue":"4","key":"1708_CR183","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1080\/17425247.2020.1730809","volume":"17","author":"B Wu","year":"2020","unstructured":"Wu B, Li A, Zhang Y, Liu X, Zhou S, Gan H, et al. Resistance of hepatocellular carcinoma to sorafenib can be overcome with co-delivery of PI3K\/mTOR inhibitor BEZ235 and sorafenib in nanoparticles. Expert Opin Drug Deliv. 2020;17(4):573\u201387.","journal-title":"Expert Opin Drug Deliv"},{"issue":"11","key":"1708_CR184","doi-asserted-by":"publisher","first-page":"10578","DOI":"10.1021\/acsami.9b00634","volume":"11","author":"Q Ning","year":"2019","unstructured":"Ning Q, Liu YF, Ye PJ, Gao P, Li ZP, Tang SY, et al. Delivery of liver-specific miRNA-122 using a targeted macromolecular prodrug toward synergistic therapy for hepatocellular carcinoma. ACS Appl Mater Interfaces. 2019;11(11):10578\u201388.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1708_CR185","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.msec.2017.08.075","volume":"83","author":"H Cheng","year":"2018","unstructured":"Cheng H, Wu Z, Wu C, Wang X, Liow SS, Li Z, et al. Overcoming STC2 mediated drug resistance through drug and gene co-delivery by PHB-PDMAEMA cationic polyester in liver cancer cells. Mater Sci Eng C Mater Biol Appl. 2018;83:210\u20137.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"6","key":"1708_CR186","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1053\/j.gastro.2008.02.028","volume":"134","author":"JG O\u2019Leary","year":"2008","unstructured":"O\u2019Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology. 2008;134(6):1764\u201376.","journal-title":"Gastroenterology"},{"issue":"2","key":"1708_CR187","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.jhep.2015.10.006","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: liver transplantation. J Hepatol. 2016;64(2):433\u201385.","journal-title":"J Hepatol"},{"issue":"6","key":"1708_CR188","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1111\/j.1399-0039.2007.00834.x","volume":"69","author":"B Afzali","year":"2007","unstructured":"Afzali B, Lechler RI, Hernandez-Fuentes MP. Allorecognition and the alloresponse: clinical implications. Tissue Antigens. 2007;69(6):545\u201356.","journal-title":"Tissue Antigens"},{"issue":"3","key":"1708_CR189","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/hep.510250328","volume":"25","author":"Banff schema for grading","year":"1997","unstructured":"Banff schema for grading. Liver allograft rejection: an international consensus document. Hepatology. 1997;25(3):658\u201363.","journal-title":"Hepatology"},{"key":"1708_CR190","volume-title":"Transplant immunology","author":"PF Halloran","year":"2015","unstructured":"Halloran PF, Kreepala C, Einecke G, Loupy A, Sellar\u00e9s J. Therapeutic approaches to organ transplantation. In: Li XC, Jevnikar AM, editors. Transplant immunology. Hoboken: Wiley; 2015."},{"issue":"1\u20132","key":"1708_CR191","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ijpharm.2011.01.018","volume":"407","author":"Y Wang","year":"2011","unstructured":"Wang Y, Wang C, Fu S, Liu Q, Dou D, Lv H, et al. Preparation of Tacrolimus loaded micelles based on poly(\u025b-caprolactone)-poly(ethylene glycol)-poly(\u025b-caprolactone). Int J Pharm. 2011;407(1\u20132):184\u20139.","journal-title":"Int J Pharm"},{"issue":"2","key":"1708_CR192","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1166\/jbn.2013.1489","volume":"9","author":"Y Wang","year":"2013","unstructured":"Wang Y, Wang C, Wang Y, Luo F, Yan X, Qian Z. Micelles of methoxy poly(ethylene glycol)-poly(epsilon-caprolactone) as a novel drug delivery vehicle for tacrolimus. J Biomed Nanotechnol. 2013;9(2):147\u201357.","journal-title":"J Biomed Nanotechnol"},{"issue":"1\u20132","key":"1708_CR193","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ijpharm.2013.10.035","volume":"460","author":"W Xu","year":"2014","unstructured":"Xu W, Ling P, Zhang T. Toward immunosuppressive effects on liver transplantation in rat model: tacrolimus loaded poly(ethylene glycol)-poly(D,L-lactide) nanoparticle with longer survival time. Int J Pharm. 2014;460(1\u20132):173\u201380.","journal-title":"Int J Pharm"},{"issue":"7","key":"1708_CR194","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1021\/acs.molpharmaceut.5b00010","volume":"12","author":"D Zhang","year":"2015","unstructured":"Zhang D, Pan X, Wang S, Zhai Y, Guan J, Fu Q, et al. Multifunctional poly(methyl vinyl ether-co-maleic anhydride)-graft-hydroxypropyl-\u03b2-cyclodextrin amphiphilic copolymer as an oral high-performance delivery carrier of Tacrolimus. Mol Pharm. 2015;12(7):2337\u201351.","journal-title":"Mol Pharm"},{"key":"1708_CR195","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.ijbiomac.2017.12.111","volume":"109","author":"TH Shin","year":"2018","unstructured":"Shin TH, Ho MJ, Kim SR, Im SH, Kim CH, Lee S, et al. Formulation and in vivo pharmacokinetic evaluation of ethyl cellulose-coated sustained release multiple-unit system of tacrolimus. Int J Biol Macromol. 2018;109:544\u201350.","journal-title":"Int J Biol Macromol"},{"issue":"4","key":"1708_CR196","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1021\/bm501847u","volume":"16","author":"M Wang","year":"2015","unstructured":"Wang M, Sun J, Zhai Y, Lian H, Luo C, Li L, et al. Enteric polymer based on pH-responsive aliphatic polycarbonate functionalized with vitamin E to facilitate oral delivery of tacrolimus. Biomacromolecules. 2015;16(4):1179\u201390.","journal-title":"Biomacromolecules"},{"issue":"1","key":"1708_CR197","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1080\/03639045.2018.1518455","volume":"45","author":"M Mohammed","year":"2019","unstructured":"Mohammed M, Mansell H, Shoker A, Wasan KM, Wasan EK. Development and in vitro characterization of chitosan-coated polymeric nanoparticles for oral delivery and sustained release of the immunosuppressant drug mycophenolate mofetil. Drug Dev Ind Pharm. 2019;45(1):76\u201387.","journal-title":"Drug Dev Ind Pharm"},{"issue":"5","key":"1708_CR198","first-page":"277","volume":"10","author":"U Hopf","year":"1980","unstructured":"Hopf U, Ramadori G. Physiology and pathophysiology of the reticuloendothelial system of the liver (author\u2019s transl). Leber Magen Darm. 1980;10(5):277\u201383.","journal-title":"Leber Magen Darm"},{"issue":"3","key":"1708_CR199","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ejpb.2010.12.029","volume":"77","author":"S Hirn","year":"2011","unstructured":"Hirn S, Semmler-Behnke M, Schleh C, Wenk A, Lipka J, Sch\u00e4ffler M, et al. Particle size-dependent and surface charge-dependent biodistribution of gold nanoparticles after intravenous administration. Eur J Pharm Biopharm. 2011;77(3):407\u201316.","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"1708_CR200","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1021\/acsnano.9b01383","volume":"13","author":"W Poon","year":"2019","unstructured":"Poon W, Zhang YN, Ouyang B, Kingston BR, Wu JLY, Wilhelm S, et al. Elimination pathways of nanoparticles. ACS Nano. 2019;13(5):5785\u201398.","journal-title":"ACS Nano"},{"key":"1708_CR201","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1743-8977-9-20","volume":"9","author":"ST Stern","year":"2012","unstructured":"Stern ST, Adiseshaiah PP, Crist RM. Autophagy and lysosomal dysfunction as emerging mechanisms of nanomaterial toxicity. Part Fibre Toxicol. 2012;9:20.","journal-title":"Part Fibre Toxicol"},{"issue":"5","key":"1708_CR202","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2217\/17435889.3.5.703","volume":"3","author":"M Longmire","year":"2008","unstructured":"Longmire M, Choyke PL, Kobayashi H. Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond). 2008;3(5):703\u201317.","journal-title":"Nanomedicine (Lond)"},{"issue":"5","key":"1708_CR203","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41563-019-0566-2","volume":"19","author":"S Sindhwani","year":"2020","unstructured":"Sindhwani S, Syed AM, Ngai J, Kingston BR, Maiorino L, Rothschild J, et al. The entry of nanoparticles into solid tumours. Nat Mater. 2020;19(5):566\u201375.","journal-title":"Nat Mater"},{"issue":"1","key":"1708_CR204","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.nantod.2012.01.002","volume":"7","author":"SC Owen","year":"2012","unstructured":"Owen SC, Chan DPY, Shoichet MS. Polymeric micelle stability. Nano Today. 2012;7(1):53\u201365.","journal-title":"Nano Today"},{"issue":"13","key":"1708_CR205","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.2174\/0929867324666171121102255","volume":"26","author":"W Fan","year":"2019","unstructured":"Fan W, Zhang L, Li Y, Wu H. Recent progress of crosslinking strategies for polymeric micelles with enhanced drug delivery in cancer therapy. Curr Med Chem. 2019;26(13):2356\u201376.","journal-title":"Curr Med Chem"},{"key":"1708_CR206","doi-asserted-by":"publisher","first-page":"111626","DOI":"10.1016\/j.msec.2020.111626","volume":"119","author":"M Lin","year":"2021","unstructured":"Lin M, Dai Y, Xia F, Zhang X. Advances in non-covalent crosslinked polymer micelles for biomedical applications. Mater Sci Eng C Mater Biol Appl. 2021;119:111626.","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"issue":"13","key":"1708_CR207","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1016\/j.biomaterials.2011.01.021","volume":"32","author":"K Xiao","year":"2011","unstructured":"Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials. 2011;32(13):3435\u201346.","journal-title":"Biomaterials"},{"issue":"25","key":"1708_CR208","doi-asserted-by":"publisher","first-page":"6574","DOI":"10.1016\/j.biomaterials.2010.05.009","volume":"31","author":"J Lipka","year":"2010","unstructured":"Lipka J, Semmler-Behnke M, Sperling RA, Wenk A, Takenaka S, Schleh C, et al. Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials. 2010;31(25):6574\u201381.","journal-title":"Biomaterials"},{"issue":"2","key":"1708_CR209","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.xphs.2018.08.008","volume":"108","author":"K Srisa-Nga","year":"2019","unstructured":"Srisa-Nga K, Mankhetkorn S, Okonogi S, Khonkarn R. Delivery of superparamagnetic polymeric Micelles loaded with quercetin to Hepatocellular Carcinoma cells. J Pharm Sci. 2019;108(2):996\u20131006.","journal-title":"J Pharm Sci"},{"issue":"4","key":"1708_CR210","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","volume":"116","author":"N Kamaly","year":"2016","unstructured":"Kamaly N, Yameen B, Wu J, Farokhzad OC. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of Controlling Drug Release. Chem Rev. 2016;116(4):2602\u201363.","journal-title":"Chem Rev"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01708-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-022-01708-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-022-01708-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T03:07:00Z","timestamp":1669000020000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-022-01708-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,19]]},"references-count":210,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1708"],"URL":"https:\/\/doi.org\/10.1186\/s12951-022-01708-y","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,19]]},"assertion":[{"value":"5 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"488"}}